4.6 Article

The speckle-type POZ protein (SPOP) inhibits breast cancer malignancy by destabilizing TWIST1

Journal

CELL DEATH DISCOVERY
Volume 8, Issue 1, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/s41420-022-01182-3

Keywords

-

Categories

Funding

  1. National Natural Science Foundation of China [82073263, 81172049, 31730017]
  2. Research Foundation of the Science and Technology Department of Sichuan Province [2022NSFSC1319]
  3. Talent Startup Foundation of Southwest Medical University [00040150]
  4. Postdoctoral Startup Foundation of Southwest Medical University [00040182]
  5. Shanghai MOST Foundation [19JC1411900]

Ask authors/readers for more resources

This study reveals a new mechanism by which SPOP regulates TWIST1 degradation in breast cancer, suppressing cancer cell migration and invasion. The expression levels of SPOP and TWIST1 are closely associated with the prognosis of breast cancer patients, particularly those with metastatic triple-negative breast cancer.
Epithelial-mesenchymal transition (EMT) inducing transcription factor TWIST1 plays a vital role in cancer metastasis. How the tumor-suppressive E3 ligase, speckle-type POZ protein (SPOP), regulates TWIST1 in breast cancer remains unknown. In this study, we report that SPOP physically interacts with, ubiquitinates, and destabilizes TWIST1. SPOP promotes K63-and K48-linked ubiquitination of TWIST1, predominantly at K73, thereby suppressing cancer cell migration and invasion. Silencing SPOP significantly enhances EMT, which accelerates breast cancer cell migration and invasiveness in vitro and lung metastasis in vivo. Clinically, SPOP is negatively correlated with the levels of TWIST1 in highly invasive breast carcinomas. Reduced SPOP expression, along with elevated TWIST1 levels, is associated with poor prognosis in advanced breast cancer patients, particularly those with metastatic triple-negative breast cancer (TNBC). Taken together, we have disclosed a new mechanism linking SPOP to TWIST1 degradation. Thus SPOP may serve as a prognostic marker and a potential therapeutic target for advanced TNBC patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available